Clinical Trial Update: Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline [Phase 3]

View source ↗

Summary

Phase 3 trial comparing two rivastigmine transdermal patch doses (10 cm^2 vs 15 cm^2) in Alzheimer’s disease patients with cognitive decline, assessing efficacy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2012-09-19